about
C-Peptide: the missing link in diabetic nephropathy?Physiological effects and therapeutic potential of proinsulin C-peptideUse of 14CO2 in estimating rates of hepatic gluconeogenesisInsulin binding monitored by fluorescence correlation spectroscopy.Effects of proinsulin C-peptide on nitric oxide, microvascular blood flow and erythrocyte Na+,K+-ATPase activity in diabetes mellitus type I.Diminished skin blood flow in Type I diabetes: evidence for non-endothelium-dependent dysfunction.Protein synthesis in skeletal muscle during starvation and refeeding: comparison of data from intact muscle and muscle biopsy material.Specific binding of proinsulin C-peptide to intact and to detergent-solubilized human skin fibroblasts.Substance P: a pioneer amongst neuropeptides.Large-surface biosensor technology for enhanced recovery in protein characterizationC-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients.Precise determination of glucose-d(2)/glucose ratio in human serum and plasma by APCI LC-MS/MS.Pentose pathway in human liverC-Peptide is Relevant in Type 1 Diabetes and its Complications: Summary and Conclusions to the Special IssueRole of C-peptide in human physiology.Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus.C-peptide: a new potential in the treatment of diabetic nephropathy.C-peptide: new findings and therapeutic implications in diabetes.C-peptide is a bioactive peptide.Symposium I: hormone-fuel interactions in normal and diabetic man. The liver as site of insulin and glucagon action in normal, diabetic and obese humans.Uptake of individual free fatty acids by skeletal muscle and liver in man.C-peptide prevents and improves chronic Type I diabetic polyneuropathy in the BB/Wor rat.C-peptide increases Na,K-ATPase expression via PKC- and MAP kinase-dependent activation of transcription factor ZEB in human renal tubular cells.Use of 2H2O for estimating rates of gluconeogenesis. Application to the fasted state.Protein dynamics in whole body and in splanchnic and leg tissues in type I diabetic patientsLiver and kidney metabolism during prolonged starvationEstimates of Krebs cycle activity and contributions of gluconeogenesis to hepatic glucose production in fasting healthy subjects and IDDM patients.C-peptide prevents glomerular hypertrophy and mesangial matrix expansion in diabetic rats.Splanchnic glucose and amino acid metabolism in obesity.Branched-chain amino acids in the treatment of chronic hepatic encephalopathy.Splanchnic and peripheral glucose and lactate metabolism during and after prolonged arm exercise.Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus.Turnover and splanchnic metabolism of free fatty acids and ketones in insulin-dependent diabetics at rest and in response to exercise.Molecular effects of proinsulin C-peptide.Proinsulin C-peptide--a consensus statement.Evidence of inter-organ amino-acid transport by blood cells in humansFree fatty acid metabolism of the human heart at rest.Influence of endogenous insulin secretion on splanchnic glucose and amino acid metabolism in man.Quantitation of the pathways of hepatic glycogen formation on ingesting a glucose loadMolecular and cellular effects of C-peptide--new perspectives on an old peptide.
P50
Q24643550-0C6BC3C2-872D-4E13-A2FF-F057E682925BQ27012286-99449299-6C1B-4535-850B-E120EEED7303Q28326550-FED293CD-2E87-42FA-9341-7A15ED58A26CQ30733750-32D237F0-02C9-4302-AE13-7B9DB0C6E29AQ30839539-BACECDA2-0032-460F-862C-58003DCBAC0DQ30993111-8EC57A5D-F704-48E1-8F22-F22A7EFD2A52Q31062585-DD6F5A77-75CB-4267-97E9-723F51D04624Q31855400-8A5A5839-3336-427A-BB1F-F81CDC6168B4Q31901693-06EE2D8F-225A-4674-ACF8-0A1F62FBC2D2Q33235740-D2BFE3B4-2359-4F9F-9A4A-CCE7A1CC9C34Q33335159-257B7F75-94DF-4105-99F0-4643DE30F75AQ33444380-98123D7A-3712-41E9-A338-90DD3B540763Q33584546-9F802A58-C448-4EE9-8CB9-9F8CA37342E3Q33682588-CBD82C0E-68BB-4FD0-9E01-ABBAD1BB79E0Q33898773-1B31BCE1-A162-40AC-8403-97188658E790Q33899769-0D29C409-F992-4FC9-97B5-08C1F0B32849Q33965004-2D83FD88-1AE3-46A3-89CB-A3A3920C44C4Q33979590-CCFDC4AA-0E36-4DBC-8D73-37786E128E6FQ34002043-820BA4A3-3F2F-4251-81BC-9F72BF9CAC17Q34035439-BD1250BC-7A2D-4476-93E2-078379A24C03Q34074225-42358F7F-D498-48E7-BE9D-4F50AE90DC44Q34087044-E5492685-241D-4919-8137-026D2834229DQ34097615-80DEB6F5-4292-4E26-9637-AB866F8828ABQ34194052-C810D140-ADF2-4177-AADB-51D13FE486EEQ34224563-A1A68CA5-923E-47F4-AFFB-35967FDC7C9FQ34239115-2A1CEAE4-F377-418E-A866-969E353985D3Q34295172-CDFEAF5C-5FE2-4ACF-A4A5-EF89744B2813Q34387122-AE32CD60-6E94-4C18-898B-4C82A8F78956Q34462199-941D210E-F647-404A-B0A3-ABACAF59A9C6Q34495382-179DB07B-51C9-4A52-97DC-53C9E9A6CB78Q34525713-8D2EB7B9-5B82-4668-9AC1-1D66569A1645Q34541876-2ACC3067-993B-429D-9379-15B21F724B6DQ34609785-413FAEE5-9FFD-4232-815E-D69740B6481CQ34756498-A1D95667-5636-460D-A76E-BC7674E7000DQ34945852-E310370C-4989-46C5-B714-8DFDE9ED9389Q35106122-54E0A8E0-2351-4545-BEE6-0617F5EE4087Q35571162-C49232D5-82BD-424D-B6D2-1C613652DC23Q35572233-848991A1-F395-4525-9485-0D7A7F1FA85AQ35583720-1550C2AF-8D9E-428B-9600-94D0B6750F35Q35805814-A5BB3B64-CB9E-4F03-9325-C65FD5BE47EA
P50
description
investigador médicu suecu
@ast
schwedischer medizinischer Wissenschaftler
@de
svensk medicinsk forskare
@sv
name
John Wahren
@ast
John Wahren
@ca
John Wahren
@en
John Wahren
@es
John Wahren
@fi
John Wahren
@fr
John Wahren
@ga
John Wahren
@nl
John Wahren
@sl
John Wahren
@sq
type
label
John Wahren
@ast
John Wahren
@ca
John Wahren
@en
John Wahren
@es
John Wahren
@fi
John Wahren
@fr
John Wahren
@ga
John Wahren
@nl
John Wahren
@sl
John Wahren
@sq
altLabel
J Wahren
@en
J. Wahren
@en
Wahren J
@en
Wahren J.
@en
Wahren
@en
prefLabel
John Wahren
@ast
John Wahren
@ca
John Wahren
@en
John Wahren
@es
John Wahren
@fi
John Wahren
@fr
John Wahren
@ga
John Wahren
@nl
John Wahren
@sl
John Wahren
@sq
P1006
P214
P244
P1006
P166
P19
P21
P213
0000 0000 8321 0759
P214
P244
P27
P31
P569
1937-04-28T00:00:00Z
P734
P735
P7859
lccn-n88616866